Slide 1: Teleflex Incorporated Third Quarter 2025 Earnings Conference Call
Teleflex Incorporated Third Quarter 2025 Earnings Conference Call 11/6/2025
Slide 2: Conference Call Logistics
Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 6, 2025 either on the Teleflex website or by telephone. The call c
Slide 3: Today's Speakers
Today’s Speakers Liam Kelly John Deren Lawrence Keusch Chairman, Executive VP VP, Investor President and CEO and CFO Relations and Strategy Development TELEFLEX EARNINGS CONFERENCE CALL 11/6/2025
Slide 4: Note on Forward-Looking Statements and Non-GAAP Financial Measures
Note on Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, our forecasted 2025: GAAP, adjusted revenue and adjusted constant currency growth, GAAP and adjusted gross and operating margins and GAAP and adjusted earnings per share and, in e
Slide 5: Executive Overview
Executive Overview Liam Kelly Chairman, President and CEO
Slide 6: Q3 Performance Summary
Q3'25 Highlights Q3 ◦ Q3'25 adjusted constant currency revenue grew 15.3% year- over-year Performance ◦ Q3'25 adjusted gross margin of 57.3% and adjusted operating margin of 23.3% Summary ◦ Q3'25 adjusted EPS of $3.67, a 5.2% increase year-over-year ◦ Lowered adjusted constant currency revenue growt
Slide 7: Q3'25 Segment Commentary
Q3'25 Segment Commentary Sales ($M) Commentary $555.9 • In Q3'25 the acquired Vascular Intervention business represented the largest contributor to growth Americas Reported rev. growth: 7.8% • Excluding Vascular Intervention, Q3'25 growth was driven by strength in our Surgical, Interventional, and A
Slide 8: Q3'25 Segment Revenue Review
Q3'25 Segment Revenue Review Three Months Ended September 28, 2025 As reported Adjusted Adjusted Constant Reported Dollars in Millions September 28, 2025 September 29, 2024 September 28, 2025 September 29, 2024 Currency Revenue Revenue Growth Growth Americas $555.9 $515.9 7.8% $555.9 $515.9 7.5% EME
Slide 9: Q3'25 Global Product Commentary
Q3'25 Global Product Commentary Sales ($M) Commentary Vascular $191.0 • In Q3'25 our broad portfolio of vascular access drove growth, including our peripheral access portfolio, Access Reported rev. growth: 5.6% EZ-IO, and central access Adj. const. curr. rev. growth: 4.3% $266.4 • Strong Q3'25 perfo
Slide 10: Q3'25 Global Product Category Revenue Review
Q3'25 Global Product Category Revenue Review Three Months Ended September 28, 2025 As reported Adjusted Adjusted Constant Reported Dollars in Millions September 28, 2025 September 29, 2024 September 28, 2025 September 29, 2024 Currency Revenue Revenue Growth Growth Vascular Access $191.0 $180.9 5.6%
Slide 11: Strategic Updates
Strategic Updates Separation of Teleflex into RemainCo and NewCo – Regarding the separation of Teleflex, decisive actions have continued to be made to unlock value within the business – In-line with Teleflex's commitment to maximizing value for its shareholders, Teleflex Board and management have be
Slide 12: Clinical and Commercial Updates
Clinical and Commercial Updates 1,000 Patients Enrolled in the BIOMAG-II Trial – BIOMAG-II, a European randomized controlled trial for the FreesolveTM resorbable magnesium scaffold, has reached the patient enrollment midpoint ahead of schedule with over 1,000 patients now enrolled – BIOMAG-II is a p
Slide 13: Financial Overview
Financial Overview John Deren Executive VP and CFO
Slide 14: Q3'25 Financial Review
Q3'25 Financial Review Revenue ($M) Gross Margin Operating Margin Earnings per Share (400) bps 5.2% $913.0 27.3% $3.49 $3.67 $892.9 (350) bps 23.3% 60.8% 19.5% $2.36 $764.4 764.4 56.3% 57.3% 49.5% (44.8)% $(9.24) Q3'24 Q3'25 Q3'24 Q3'25 Q3'24 Q3'25 Q3'24 Q3'25 Q3'24 Q3'25 Q3'24 Q3'25 Q3'24 Q3'25 Q3'
Slide 15: 2025 Financial Guidance Summary
2025 Financial Guidance Summary 2025 Guidance Low High GAAP Revenue Growth 9.10% 9.60% Impact of Foreign Exchange Rate Fluctuations 1.00% 1.00% Impact of Italian Payback Measure 1.20% 1.20% Adjusted Constant Currency Revenue Growth 6.90% 7.40% Adjusted Gross Margin 58.75% 59.50% Adjusted Operating M
Slide 16: Forecasted 2025 Adjusted Constant Currency Revenue Growth Reconciliation
Forecasted 2025 Adjusted Constant Currency Revenue Growth Reconciliation 2025 Guidance 2025 Guidance 2024 Low High GAAP revenue $3,047.3 $3,325 $3,340 % growth — 9.1% 9.6% Italian payback measure adjustment $(13.8) $20.1 $20.1 Adjusted revenue $3,061.1 $3,305 $3,320 % growth — 8.0% 8.5% Estimated im
Slide 17: Key Takeaways
Key Takeaways We continued to make The Vascular Intervention We continue to advance our significant progress in business performed well in the strategic objectives. Our focus is executing our strategy. Third quarter with revenue exceeding on enhanced operational quarter revenue was in the our guidan
Slide 18: Thank You!
Thank You! 18 TELEFLEX EARNINGS CONFERENCE CALL 11/6/2025
Slide 19: Appendices
Appendices Empowering the future of healthcare
Slide 20: Non-GAAP Financial Measures
Non-GAAP Financial Measures The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: Adjusted revenue. This non-GAAP measure
Slide 21: Non-GAAP Adjustments
Non-GAAP Adjustments The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached: Restructuring and rationalization charges - Restructuring and rat
Slide 22: Non-GAAP Adjustments
Non-GAAP Adjustments European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, inc
Slide 23: Appendix A1 - Q3'25 Segment Reconciliation of Net Revenue
Appendix A1 - Q3'25 Segment Reconciliation of Net Revenue (Dollars in millions) Three Months Ended September 28, 2025 September 28, 2025 September 29, 2024 % Increase / (Decrease) Adjusted Reported Adjusted Reported Adjusted Reported Adjustment Constant Adjustment Adjustment Revenue Revenue Revenue
Slide 24: Appendix A2 - 2025 Segment Reconciliation of Net Revenue
Appendix A2 - 2025 Segment Reconciliation of Net Revenue (Dollars in millions) Nine Months Ended September 28, 2025 September 28, 2025 September 29, 2024 % Increase / (Decrease) Adjusted Reported Adjusted Reported Adjusted Reported Adjustment Constant Adjustment Adjustment Revenue Revenue Revenue Re
Slide 25: Appendix A3 - Q3'25 Global Product Category Reconciliation of Net Revenue
Appendix A3 - Q3'25 Global Product Category Reconciliation of Net Revenue (Dollars in millions) Three Months Ended September 28, 2025 September 28, 2025 September 29, 2024 % Increase / (Decrease) Adjusted Reported Adjusted Reported Adjusted Reported Adjustment Constant Adjustment Adjustment Revenue
Slide 26: Appendix A4 - 2025 Global Product Category Reconciliation of Net Revenue
Appendix A4 - 2025 Global Product Category Reconciliation of Net Revenue (Dollars in millions) Nine Months Ended September 28, 2025 September 28, 2025 September 29, 2024 % Increase / (Decrease) Adjusted Reported Adjusted Reported Adjusted Reported Adjustment Constant Adjustment Adjustment Revenue Re
Slide 27: Appendix B1 – Reconciliation of Consolidated Statement of Income Items
Appendix B1 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Three Months Ended September 28, 2025 (Loss) Effective Diluted (loss) earnings per Revenue Gross margin SG&A (1) R&D (1) Operating Income Income tax income tax share from continuing ma
Slide 28: Appendix B2 – Reconciliation of Consolidated Statement of Income Items
Appendix B2 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Three Months Ended September 29, 2024 Income Effective Diluted earnings Revenue Gross SG&A (1) R&D (1) Operating before Income tax income tax per share from margin margin (2) income ta
Slide 29: Appendix B3 – Reconciliation of Consolidated Statement of Income Items
Appendix B3 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Nine Months Ended September 28, 2025 (Loss) Effective Diluted (loss) earnings per Revenue Gross margin SG&A (1) R&D (1) Operating Income Income tax income tax share from continuing mar
Slide 30: Appendix B4 – Reconciliation of Consolidated Statement of Income Items
Appendix B4 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Nine Months Ended September 29, 2024 Diluted earnings Revenue Gross SG&A (1) R&D (1) Operating Income before Income tax Effective per share from margin margin (2) income taxes expense
Slide 31: Appendix B Tickmarks
A. Restructuring and rationalization charges – For the three months ended September 28, 2025, pre-tax restructuring charges were $1.6 million and restructuring related charges were $4.5 million. For the three months ended September 29, 2024, pre-tax restructuring charges were $0.3 million and restru
Slide 32: Appendix C - 2025 Adj. Gross and Operating Margin Guidance Reconciliation
Appendix C - 2025 Adj. Gross and Operating Margin Guidance Reconciliation Low High Forecasted GAAP Gross Margin 52.56% 53.31% Estimated restructuring and rationalization items 0.61% 0.61% Estimated acquisition, integration and divestiture related items 2.13% 2.13% Italian payback measure (0.29)% (0.
Slide 33: Appendix D - Reconciliation of Forecasted 2025 Adjusted EPS Guidance
Appendix D - Reconciliation of Forecasted 2025 Adjusted Earnings Per Share Guidance Low High Forecasted GAAP Diluted Earnings Per Share from continuing operations $(4.42) $(4.22) Restructuring and rationalization items, net of tax $0.51 $0.51 Impairment items, net of tax $10.89 $10.89 Acquisition, i
Slide 34: 2025 Financial Review - Nine Months Ended September 28, 2025
2025 Financial Review - Nine Months Ended September 28, 2025 ◦ Revenue increased 6.3% year-over-year on a GAAP basis Global revenue growth ◦ Adjusted revenue increased 4.3% year-over-year on a constant currency basis ◦ GAAP gross margin of 53.1% vs. 56.1% in the prior year period Gross margin ◦ Adju